Sight Sciences, Inc. (NASDAQ:SGHT) COO Sells $20,690.24 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) COO Sam Boong Park sold 3,403 shares of the firm’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $6.08, for a total transaction of $20,690.24. Following the transaction, the chief operating officer now owns 254,826 shares in the company, valued at approximately $1,549,342.08. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Sight Sciences Stock Performance

Shares of SGHT stock traded down $0.18 on Thursday, hitting $6.00. The company’s stock had a trading volume of 149,380 shares, compared to its average volume of 197,109. The company has a market capitalization of $298.54 million, a PE ratio of -5.36 and a beta of 2.71. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.50 and a current ratio of 11.01. Sight Sciences, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $8.45. The stock’s 50 day moving average is $6.54 and its 200-day moving average is $6.23.

Sight Sciences (NASDAQ:SGHT) last posted its earnings results on Thursday, August 1st. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.06. The firm had revenue of $21.37 million during the quarter, compared to analysts’ expectations of $21.32 million. Sight Sciences had a negative net margin of 65.90% and a negative return on equity of 45.68%. During the same quarter in the prior year, the business earned ($0.30) earnings per share. Equities research analysts expect that Sight Sciences, Inc. will post -1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Citigroup raised their price objective on shares of Sight Sciences from $6.00 to $6.50 and gave the stock a “neutral” rating in a report on Wednesday, July 10th. Morgan Stanley lifted their price target on shares of Sight Sciences from $5.40 to $6.50 and gave the company an “equal weight” rating in a report on Monday, July 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a research note on Friday, August 2nd. Finally, Lake Street Capital assumed coverage on shares of Sight Sciences in a research report on Wednesday, August 21st. They set a “buy” rating and a $10.00 price target for the company. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $7.25.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SGHT. RTW Investments LP bought a new position in Sight Sciences during the 4th quarter valued at $850,000. Jacobs Levy Equity Management Inc. raised its stake in Sight Sciences by 25.5% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 377,057 shares of the company’s stock valued at $1,991,000 after acquiring an additional 76,549 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Sight Sciences by 51.9% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,653 shares of the company’s stock valued at $141,000 after acquiring an additional 9,106 shares during the period. Vanguard Group Inc. raised its stake in Sight Sciences by 5.5% in the 1st quarter. Vanguard Group Inc. now owns 1,556,450 shares of the company’s stock valued at $8,218,000 after acquiring an additional 81,768 shares during the period. Finally, Acadian Asset Management LLC grew its holdings in Sight Sciences by 256.6% during the 2nd quarter. Acadian Asset Management LLC now owns 83,693 shares of the company’s stock valued at $556,000 after buying an additional 60,220 shares in the last quarter. Institutional investors own 55.51% of the company’s stock.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.